natgillin/translations-raw huggingface dataset:
NAME OF THE MEDICINAL PRODUCT EVOTAZ 300 mg/150 mg film-coated tablets atazanavir/cobicistat
EVOTAZ 300 mg/150 mg filmom obložene tablete atazanavir/kobicistat
EVOTAZ should be used with caution in patients with mild hepatic impairment.
EVOTAZ treba primjenjivati uz oprez u bolesnika s blagim oštećenjem jetrene funkcije.
Co-administration of boceprevir and EVOTAZ is not recommended.
Ne preporučuje se istodobna primjena boceprevira i lijeka EVOTAZ.
Simeprevir may increase atazanavir and/or cobicistat plasma concentrations.
Simeprevir može povisiti plazmatske koncentracije atazanavira i/ili kobicistata.
It is especially important to mention these: medicines containing ritonavir or cobicistat (booster agents) other medicines to treat HIV infection (e.g. indinavir, didanosine, tenofovir disoproxil, tenofovir alafenamide, efavirenz, etravirine, nevirapine and maraviroc) boceprevir, simeprevir and sofosbuvir/velpatasvir/voxilaprevir (used to treat hepatitis C) sildenafil, vardenafil and tadalafil (used by men to treat impotence [erectile dysfunction]) if you are taking an oral contraceptive ("the Pill") any medicines used to treat diseases related to the acid in the stomach (e.g. antacids, H2-blockers like famotidine and proton pump inhibitors like omeprazole) disopyramide, flecainide, mexiletine, propafenone, digoxin, bosentan, amlodipine, felodipine, nicardipine, nifedipine, verapamil, diltiazem, metoprolol and timolol (medicines to lower blood pressure, to slow heart rate or to correct heart rhythm) atorvastatin, pravastatin, fluvastatin, pitavastatin and rosuvastatin (used to lower blood cholesterol) salmeterol (used to treat asthma) ciclosporin, tacrolimus and sirolimus (medicines to decrease the effects of body's immune system) certain antibiotics (rifabutin, clarithromycin) ketoconazole, itraconazole, voriconazole and fluconazole (antifungals) metformin (used to treat type 2 diabetes) warfarin, rivaroxaban and dabigatran (anticoagulants, used to reduce blood clots) irinotecan, dasatinib, nilotinib, vinblastine and vincristine (used to treat cancer) trazodone (used to treat depression)
Osobito je važno da spomenete sljedeće: lijekove koji sadrže ritonavir ili kobicistat (pojačivače) druge lijekove za liječenje HIV infekcije (npr. indinavir, didanozin, tenofovirdizoproksil, tenofoviralafenamid, efavirenz, etravirin, nevirapin i maravirok) boceprevir, simeprevir i sofosbuvir/velpatasvir/voksilaprevir (koji se koriste u liječenju hepatitisa C) sildenafil, vardenafil i tadalafil (uzimaju ih muškarci za liječenje impotencije [erektilne disfunkcije]) ako uzimate oralnu kontracepciju ("pilule") bilo koji lijek za liječenje bolesti povezanih s kiselinom u želucu (npr. antacide, H2blokatore poput famotidina i inhibitore protonske pumpe poput omeprazola) dizopiramid, flekainid, meksiletin, propafenon, digoksin, bosentan, amplodipin, felodipin, nikardipin, nifedipin, verapamil, diltiazem, metoprolol i timolol (lijekovi za snižavanje krvnog tlaka, usporavanje rada srca ili ispravljanje srčanog ritma) atorvastatin, pravastatin, fluvastatin, pitavastatin i rosuvastatin (primjenjuju se za snižavanje razine kolesterola u krvi) salmeterol (primjenjuje se za liječenje astme) ciklosporin, takrolimus i sirolimus (lijekovi za smanjenje učinaka imunosnog sustava tijela) određene antibiotike (rifabutin, klaritromicin) ketokonazol, itrakonazol, vorikonazol i flukonazol (lijekovi za liječenje gljivičnih infekcija)
Common (may affect up to 1 in 10 people) increased appetite, dysgeusia (impairment of the sense of taste), dry mouth headache, dizziness insomnia (difficulty sleeping), abnormal dreams, somnolence (sleepiness) vomiting, diarrhoea, abdominal pain (stomach pain of discomfort), dyspepsia (indigestion), bloated or distended tummy (abdomen), flatulence (wind) hyperbilirubinaemia (increased levels of bilirubin in the blood) rash fatigue (extreme tiredness)
Često (mogu se javiti u do 1 na 10 osoba) pojačan tek, disgeuzija (poremećaj osjeta okusa), suha usta glavobolja, omaglica nesanica (poteškoće sa spavanjem), neuobičajeni snovi, somnolencija (pospanost) povraćanje, proljev, bol u abdomenu (bol ili nelagoda u trbuhu), dispepsija (probavne tegobe), nadutost ili rastezanje trbuha, flatulencija (vjetrovi) hiperbilirubinemija (povišene razine bilirubina u krvi) osip iscrpljenost (izrazit umor)
The mechanism of interaction is inhibition of CYP2D6 by cobicistat.
Mehanizam interakcije je inhibicija CYP2D6 koju uzrokuje kobicistat.
Uncommon (may affect up to 1 in 100 people) torsade de pointes (life threatening irregular heart beat) hypersensitivity (allergic reaction) anorexia (loss of appetite), weight loss, weight gain depression, anxiety, sleep disorder disorientation, amnesia (loss of memory) peripheral neuropathy (numbness, weakness, tingling or pain in the arms and legs) syncope (fainting), hypertension (high blood pressure) dyspnoea (shortness of breath) pancreatitis (inflammation of the pancreas), gastritis (inflammation of the stomach), stomatitis aphthous (mouth ulcers and cold sores) hepatitis (inflammation of the liver) angioedema (severe swelling of the skin and other tissues most often the lips or the eyes) urticaria (itchy rash), alopecia (unusual hair loss or thinning), pruritus (itching) muscle atrophy (muscle shrinkage), arthralgia (joint pain), myalgia (aching muscles) nephrolithiasis (formation of kidney stones), interstitial nephritis (kidney inflammation), hematuria (blood in the urine), proteinuria (excess protein in the urine), pollakiuria (increased frequency of urination), chronic kidney disease (how well your kidneys work) gynaecomastia (breast enlargement in men) chest pain, malaise (generally feeling unwell), fever asthenia (unusual tiredness or weakness) serious skin rashes (allergic reactions including rash, a high temperature, increased levels of liver enzymes seen in blood tests, an increase in a type of white blood cell [esosinophilia] and/or enlarged lymph nodes) (see section 2) gallbladder disorders (gallstones and gallbladder inflammation)
Manje često (mogu se javiti u do 1 na 100 osoba) torsade de pointes (po život opasna nepravilnost srčanog ritma) preosjetljivost (alergijska reakcija) anoreksija (gubitak teka), gubitak tjelesne težine, povećanje tjelesne težine depresija, tjeskoba, poremećaj spavanja dezorijentacija, amnezija (gubitak pamćenja) periferna neuropatija (utrnulost, slabost, trnci ili bol u rukama i nogama) sinkopa (nesvjestica), hipertenzija (visok krvni tlak) dispneja (nedostatak zraka) pankreatitis (upala gušterače), gastritis (upala želuca), aftozni stomatitis (vrijedovi i afte u ustima) hepatitis (upala jetre) angioedem (teško oticanje kože i drugih tkiva , najčešće usana i očiju) urtikarija (osip koji svrbi), alopecija (neuobičajeno opadanje ili stanjivanje kose), pruritus (svrbež) mišićna atrofija (smanjenje mišića), artralgija (bol u zglobovima), mialgija (bol u mišićima) nefrolitijaza (stvaranje bubrežnih kamenaca), intersticijski nefritis (upala bubrega), hematurija (krv u mokraći), proteinurija (višak proteina u mokraći), polakizurija (učestalo mokrenje), kronična bubrežna bolest (kako dobro rade vaši bubrezi) ginekomastija (povećanje grudi u muškaraca) bol u prsištu, malaksalost (opće loše osjećanje), vrućica astenija (neuobičajen umor ili slabost) ozbiljni kožni osipi (alergijske reakcije koje uključuju osip, povišenu tjelesnu temperaturu, povišene razine jetrenih enzima u nalazima krvnih pretraga, povišen broj određene vrste bijelih krvnih stanica [eozinofilija] i/ili povećane limfne čvorove) (pogledajte dio 2.)
Cobicistat does not select any HIV resistance mutations, due to its lack of antiviral activity.
Budući da kobicistat nema antivirusnu aktivnost, on ne izdvaja mutacije HIV virusa koje uzrokuju rezistenciju.
25-O-desacetyl-rifabutin AUC
25-O-dezacetil-rifabutin AUC ↑990%
Atazanavir, an active component of EVOTAZ, has been detected in human milk.
Atazanavir, djelatna tvar lijeka EVOTAZ pronađena je u majčinom mlijeku.
Midazolam and triazolam are extensively metabolized by CYP3A4.
Midazolam i triazolam opsežno se metaboliziraju putem CYP3A4.
Cobicistat is a strong mechanism-based CYP3A inhibitor and is a CYP3A substrate.
Kobicistat je snažan inhibitor CYP3A temeljeno na mehanizmu i supstrat za CYP3A.
No significant effect on atazanavir concentrations was observed.
Nije opažen značajan učinak na koncentracije atazanavira.
Atazanavir plasma concentrations may decrease as a consequence of a reduction in cobicistat plasma concentrations, which may result in loss of therapeutic effect and development of resistance.
Zbog sniženja plazmatskih koncentracija kobicistata mogu se sniziti i plazmatske koncentracije atazanavira, što za posljedicu može imati gubitak terapijskog učinka i razvoj rezistencije.
EVOTAZ should be used with caution in patients with mild hepatic impairment (see sections 4.2, 4.3 and 5.2).
EVOTAZ treba primjenjivati uz oprez u bolesnika s blagim oštećenjem jetrene funkcije (vidjeti dijelove 4.2, 4.3 i 5.2).
Co-administration of EVOTAZ with proton pump inhibitors (PPIs) is not recommended due to the decreased solubility of atazanavir as intra-gastric pH increase with PPIs (see section 4.5).
Ne preporučuje se istodobna primjena lijeka EVOTAZ s inhibitorima protonske pumpe jer se topljivost atazanavira smanjuje s povećanjem želučanog pH uzrokovanim primjenom inhibitora protonske pumpe (vidjeti dio 4.5).
Co-administration of tenofovir DF with cobicistat is expected to increase tenofovir plasma concentrations.
Očekuje se da će istodobna primjena tenofovira DF i kobicistata povisiti plazmatske koncentracije tenofovira.
if you have type A or B haemophilia if you have problems with your kidneys or require haemodialysis.
A ili B ako imate bubrežne tegobe koje zahtijevaju hemodijalizu.
Rifabutin 150 mg every other day/elvitegravir 150 mg once daily/cobicistat 150 mg once daily
Rifabutin 150 mg svaki drugi dan/elvitegravir 150 mg jedanput na dan/kobicistat 150 mg jedanput na dan
Raltegravir 400 mg twice daily (atazanavir 400 mg)
Raltegravir 400 mg dvaput na dan (atazanavir 400 mg)
(atazanavir 300 mg once daily with cobicistat 150 mg once daily)
(atazanavir 300 mg jedanput na dan s kobicistatom 150 mg jedanput na dan)
Clinical monitoring may be needed upon co-administration with EVOTAZ.
Možda će biti potrebno kliničko praćenje nakon istodobne primjene s lijekom EVOTAZ.
Cobicistat is a CYP3A substrate and is metabolised to a minor extent by CYP2D6.
Kobicistat je supstrat za CYP3A i u manjoj se mjeri metabolizira putem CYP2D6.
Stevens-Johnson syndrome (SJS), erythema multiforme, toxic skin eruptions and drug rash with eosinophilia and systemic symptoms (DRESS) syndrome have been reported with the use of atazanavir (see section 4.4).
Kod primjene atazanavira prijavljeni su Stevens-Johnsonov sindrom (SJS), multiformni eritem, toksične kožne erupcije i medikamentozni osip praćen eozinofilijom i sistemskim simptomima (DRESS) (vidjeti dio 4.4).
If you develop signs or symptoms of kidney stones (pain in your side, blood in your urine, pain when you urinate), please inform your doctor immediately if you are taking oral contraceptives ("the Pill") to prevent pregnancy.
Ako razvijete znakove ili simptome bubrežnih kamenaca (bol u slabinama, krv u mokraći, bol pri mokrenju), odmah o tome obavijestite svog liječnika.
Drospirenone/ethinyloestradiol 3 mg/0.02 mg single dose (atazanavir 300 mg once daily with cobicistat 150 mg once daily)
Drospirenon/etinilestradiol 3 mg/0,02 mg u jednokratnoj dozi (atazanavir 300 mg jednom dnevno s kobicistatom150 mg jednom dnevno)
Co-administration of EVOTAZ with glecaprevir/pibrentasvir fixed dose combination is contraindicated because of the potential increase in the risk of ALT elevations due to a significant increase in glecaprevir and pibrentasvir plasma concentrations (see section 4.3).
Istodobna primjena lijeka EVOTAZ s fiksnom kombinacijom glekaprevir/pibrentasvir je kontraindicirana zbog mogućeg povećanog rizika povišenja ALT-a zbog značajnog povišenja koncentracije glekaprevira i pibrentasvira u plazmi (vidjeti dio 4.3).
The effect of EVOTAZ on fertility in humans has not been studied.
Nije ispitivan učinak lijeka EVOTAZ na plodnost ljudi.
No clinically relevant pharmacokinetic differences due to ethnicity have been identified for atazanavir or cobicistat.
Nisu identificirane klinički značajne farmakokinetičke razlike uvjetovane etničkim podrijetlom koje bi bile povezane s atazanavirom ili kobicistatom.
There are limited data from the use of EVOTAZ in pregnant women.
Podaci o primjeni lijeka EVOTAZ u trudnica su ograničeni.
Clinical monitoring of therapeutic effect and adverse events is recommended when these medicinal products are co-administered with EVOTAZ.
Preporučuje se kliničko praćenje terapijskih učinaka i nuspojava pri istodobnoj primjeni navedenih lijekova s lijekom EVOTAZ.
Tenofovir disoproxil fumarate (tenofovir DF) 300 mg once daily (atazanavir 400 mg once daily)
Tenofovirdizoproksilfumarat (tenofovir DF) 300 mg jedanput na dan (atazanavir 400 mg jedanput na dan)
Omeprazole 40 mg once daily (atazanavir 400 mg once daily, 2 hours after omeprazole)
Omeprazol 40 mg jedanput na dan (atazanavir 400 mg jedanput na dan, 2 sata nakon omeprazola)
Cobicistat is metabolised via CYP3A (major)- and CYP2D6 (minor)-mediated oxidation and does not undergo glucuronidation.
Kobicistat se metabolizira oksidacijom u kojoj posreduju CYP3A (glavni put) i CYP2D6 (sporedni put) te ne prolazi glukuronidaciju.
14-OH clarithromycin Cmax ↓72%
14-OH klaritromicin Cmax ↓72% (↓76%
The mechanism of interaction is CYP3A4 inhibition by atazanavir, cobicistat and ketoconazole or itraconazole.
Mehanizam interakcije je inhibicija CYP3A4 koju uzrokuju atazanavir, kobicistat i ketokonazol ili itrakonazol.
Co-administration of EVOTAZ with voxilaprevir-containing products is expected to increase the concentration of voxilaprevir.
Očekivano je da istodobna primjena lijeka EVOTAZ s lijekovima koji sadrže voksilaprevir povisi koncentraciju voksilaprevira.
Amiodarone Dronedarone Quinidine Systemic lidocaine
Amiodaron Dronedaron Kinidin
Dose related asymptomatic prolongations in PR interval with atazanavir, a component of EVOTAZ have been observed in clinical studies.
U kliničkim su ispitivanjima opažena asimptomatska produljenja PR-intervala povezana s dozom atanazavira, sastavnicom lijeka EVOTAZ.
Atazanavir and cobicistat are metabolised by the hepatic system.
Atazanavir i kobicistat se metaboliziraju putem jetre.
Efavirenz 600 mg single dose (cobicistat 150 mg once daily)
Efavirenz 600 mg u jednokratnoj dozi (kobicistat 150 mg jedanput na dan)
14-OH clarithromycin Cmin ↓62%
14-OH klaritromicin Cmin ↓62% (↓66%
Nephrolithiasis has been reported in patients receiving atazanavir (see section 4.8).
U bolesnika koji su primali atazanavir prijavljena je nefrolitijaza (vidjeti dio 4.8).
Cobicistat is a selective, mechanism-based inhibitor of cytochromes P450 of the CYP3A subfamily.
Kobicistat je selektivni inhibitor citokroma P450 podobitelji CYP3A temeljeno na mehanizmu.
Didanosine (enteric coated capsules) 400 mg single dose (atazanavir 400 mg once daily)
Didanozin (želučanootporne kapsule) 400 mg u jednokratnoj dozi (atazanavir 400 mg jedanput na dan)
Co-administration of salmeterol with EVOTAZ is not recommended (see section 4.4).
Ne preporučuje se istodobna primjena salmeterola i lijeka EVOTAZ (vidjeti dio 4.4).
Co-administration with EVOTAZ has the potential to produce serious and/or life-threatening adverse reactions.
Istodobna primjena s lijekom EVOTAZ može uzrokovati ozbiljne i/ili po život opasne nuspojave.
Cobicistat, a component of EVOTAZ, has been shown to decrease estimated creatinine clearance due to inhibition of tubular secretion of creatinine.
Pokazalo se da kobicistat, sastavnica lijeka EVOTAZ, smanjuje procijenjeni klirens kreatinina zbog inhibicije tubularne sekrecije kreatinina.
AUC ↑247% (↑229% ↑267%) Cmax ↑216% (↑200% ↑233%) Cmin ↑273% (↑254% ↑293%)
AUC ↑247% (↑229% ↑267%) Cmax ↑216% (↑200% ↑233%)
Co-administration of EVOTAZ with medicinal products that inhibit CYP3A may result in increased plasma concentration of atazanavir and/or cobicistat.
Istodobna primjena lijeka EVOTAZ i lijekova koji inhibiraju CYP3A može povisiti plazmatske koncentracije atazanavira i/ili kobicistata.
Naloxone AUC: ↓28% Naloxone Cmax: ↓28%
Nalokson AUC: ↓28% Nalokson Cmax: ↓28%
gait disturbance (abnormal manner of walking) oedema (swelling), palpitation (fast or irregular heart beat) hepatosplenomegaly (enlargement of the liver and spleen) vesiculobullous rash (visible accumulation of fluid under the skin), eczema (skin rash), vasodilatation (widening of blood vessels)
Rijetke (mogu se javiti u do 1 na 1000 osoba) produljenje QTc-intervala (nepravilan srčani ritam) poremećaj hoda (neuobičajen način hodanja) edem (oticanje), palpitacije (ubrzan ili nepravilan srčani ritam) hepatosplenomegalija (povećanje jetre i slezene) vezikulobulozni osip (vidljivo nakupljanje tekućine pod kožom), ekcem (kožni osip), vazodilatacija (proširenje krvnih žila)
Elbasvir concentrations were increased when co-administered with atazanavir/ritonavir
Koncentracije elbasvira bile su povišne s istodobnom primjenom atazanavira/ritonavira
Stevens-Johnson syndrome (SJS), erythema multiforme, toxic skin eruptions and drug rash with eosinophilia and systemic symptoms (DRESS) syndrome have been reported in patients receiving atazanavir.
U bolesnika koji su primali atazanavir prijavljeni su Stevens-Johnsonov sindrom (SJS), multiformni eritem, toksične kožne erupcije i medikamentozni osip praćen eozinofilijom i sistemskim simptomima (engl. drug rash with eosinophilia and systemic symptoms, DRESS).
Co-administration of EVOTAZ and nevirapine is not recommended and may result in a loss of therapeutic effect of EVOTAZ and development of resistance to atazanavir.
Ne preporučuje se istodobna primjena lijeka EVOTAZ i nevirapina jer može dovesti do gubitka terapijskog učinka lijeka EVOTAZ i razvoja rezistencije na atazanavir.
Hepatobiliary disorders very common jaundice common hyperbilirubinaemia uncommon hepatitis, cholelithiasisa, cholestasisa rare hepatosplenomegaly, cholecystitisa
Poremećaji jetre i žuči vrlo često žutica često hiperbilirubinemija manje često hepatitis, kolelitijazaa, kolestazaa rijeko hepatosplenomegalija, kolecistitisa
Co-administration of tenofovir alafenamide with cobicistat is expected to increase tenofovir alafenamide and tenofovir plasma concentrations.
Pri istodobnoj primjeni tenofoviralafenamida s kobicistatom, očekuju se povećane koncentracije tenofoviralafenamida i tenofovira u plazmi.
ACID REDUCING AGENTS
LIJEKOVI ZA SMANJENJE KOLIČINE ŽELUČANE KISELINE
More frequent therapeutic concentration monitoring is recommended for immunosuppressant agents when co-administered with EVOTAZ.
Preporučuje se učestalija kontrola terapijskih koncentracija imunosupresiva pri njihovoj istodobnoj primjeni s lijekom EVOTAZ.
Studies in animals have been shown excretion of cobicistat/metabolites in milk Because of both the potential for HIV transmission and the potential for serious adverse reactions in breast-feeding infants, women should be instructed not to breast-feed if they are receiving EVOTAZ.
Zbog mogućnosti prijenosa HIV-a na dojenčad i pojave ozbiljnih nuspojava u dojenčadi, žene treba uputiti da ne doje ako primaju EVOTAZ.
Co-administration of etravirine and EVOTAZ is expected to decrease atazanavir and cobicistat plasma concentrations.
Očekuje se da će istodobna primjena etravirina i lijeka EVOTAZ sniziti plazmatske koncentracije atazanavira i kobicistata.
300 mg tenofovir disoproxil fumarate is equivalent to 245 mg tenofovir disoproxil.
245 mg tenofovirdizoproksila.
Cholelithiasis has been reported in patients receiving atazanavir (see section 4.8).
U bolesnika koji su primali atazanavir prijavljena je kolelitijaza (vidjeti dio 4.8).
The mechanism of interaction is decreased solubility of atazanavir as intra-gastric pH increases with proton pump inhibitors.
Mehanizam interakcije je smanjena topljivost atazanavira zbog povišenog želučanog pH koji uzrokuju inhibitori protonske pumpe.
Co-administration of EVOTAZ with astemizole and terfenadine is contraindicated (see section 4.3).
Istodobna primjena lijeka EVOTAZ s astemizolom i terfenadinom je kontraindicirana (vidjeti dio 4.3).
The mechanism is UGT1A1 inhibition by atazanavir.
Mehanizam je inhibicija UGT1A1 koju uzrokuje atazanavir.
The mechanism of interaction is inhibition of CYP3A4 and/or CYP2D6 by atazanavir and/or cobicistat.
Mehanizam interakcije je inhibicija CYP3A4 i/ili CYP2D6 koju uzrokuju atazanavir i/ili kobicistat.
Co-administration of EVOTAZ and elbasvir/grazoprevir is contraindicated because of the expected increase in grazoprevir plasma concentrations and the associated potential increase in the risk of ALT elevations (see section 4.3).
Istodobna primjena lijeka EVOTAZ s elbasvirom/grazoprevirom je kontraindicirana zbog očekivanog povišenja koncentracije grazoprevira u plazmi, te povezanim mogućim povećanim rizikom povišenja ALT-a (vidjeti dio 4.3).
Telaprevir 750 mg three times daily (atazanavir/ritonavir 300/100 mg once daily)
Telaprevir 750 mg triput na dan (atazanavir/ritonavir 300/100 mg jedanput na dan)
GASTROINTESTINAL MOTILITY AGENTS Cisapride
LIJEKOVI ZA MOTILITET PROBAVNOG SUSTAVA Cisaprid
Voxilaprevir AUC : ↑331%
Voksilaprevir AUC: ↑331% (↑276%
The combination of rifampicin and EVOTAZ is contraindicated (see section 4.3).
Kombinacija rifampicina i lijeka EVOTAZ je kontraindicirana (vidjeti dio 4.3).
EVOTAZ is not recommended in patients undergoing haemodialysis (see sections 4.2 and 5.2).
Primjena lijeka EVOTAZ ne preporučuje se u bolesnika na hemodijalizi (vidjeti dijelove 4.2 i 5.2).
Buprenorphine, once daily, stable maintenance dose (atazanavir 300 mg once daily with ritonavir 100 mg once daily)
Buprenorfin, jedanput na dan, stabilna doza održavanja (atazanavir 300 mg jedanput na dan i ritonavir 100 mg jedanput na dan)
Coadministration of EVOTAZ with voxilaprevir-containing regimens is not recommended.
Ne preporučuje se istodobna primjena lijeka EVOTAZ s režimima koji uključuju voksilaprevir.
Glecaprevir 300 mg/pibrentasvir 120 mg once daily (atazanavir 300 mg with ritonavir 100 mg once daily*)
Glekaprevir 300 mg/pibrentasvir 120 mg jednom dnevno (atazanavir 300 mg s ritonavirom 100 mg jednom dnevno*)
Increased plasma concentrations of medicinal products that are metabolised by CYP3A (including atazanavir) are observed on co-administration with cobicistat.
Kod istodobne primjene s kobicistatom primijećene su povišene plazmatske koncentracije lijekova koji se metaboliziraju putem CYP3A (uključujući atazanavir).
Tell your doctor if you notice anything unusual about your health.
Ako primijetite bilo što neobično u vezi sa svojim zdravljem, obavijestite o tome svog liječnika.
EVOTAZ is not recommended for co-administration with etravirine because it may result in the loss of therapeutic effect and development of resistance to atazanavir.
Ne preporučuje se istodobna primjena lijeka EVOTAZ i etravirina jer može dovesti do gubitka terapijskog učinka lijeka EVOTAZ i razvoja rezistencije na atazanavir.
The mechanism of interaction is decreased solubility of atazanavir as intra-gastric pH increases with H2 blockers.
Mehanizam interakcije je smanjena topljivost atazanavira zbog povišenog želučanog pH koji uzrokuju blokatori H2-receptora.
Atazanavir with cobicistatf (n = 344)
144. tjedan Atazanavir s Atazanavir s Atazanavir s Atazanavir s kobicistatomf (n = 344)
The mechanism of interaction is CYP3A4 induction by rifampicin.
Mehanizam interakcije je indukcija CYP3A4 koju uzrokuje rifampicin.
The combination of pimozide, quetiapine or lurasidone and EVOTAZ is contraindicated (see section 4.3).
Kombinacija pimozida kvetiapina ili lurasidona s lijekom EVOTAZ je kontraindicirana (vidjeti dio
Hyperbilirubinaemia (an increase in the level of bilirubin in the blood) has occurred in patients receiving EVOTAZ.
U bolesnika koji uzimaju EVOTAZ može se razviti hiperbilirubinemija (povišena razina bilirubina u krvi).
No significant effect on methadone concentrations was observed when co-administered with atazanavir.
Nisu opaženi značajni učinci na koncentraciju metadona kod istodobne primjene s atazanavirom.